About: Prolonged survival of patients with peripheral T-Cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prolonged survival of patients with peripheral T-Cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Background: Nodal peripheral T-cell lymphomas (PTCLs) are infrequent subtypes of non-Hodgkin?s lymphomas.-The WHO classification recognizes three subgroups of nodal PTCL: peripheral T-cell lymphoma not otherwise specified-(PTCL, NOS), anaplastic large cell lymphoma (ALCL) and angioimmunoblastic lymphoma (AIL). The clinical-course is aggressive and despite multiagent chemotherapy, the median survival is about 2 years. Optimal first-line chemotherapy-is not established and the role of high-dose therapy with autologous stem cell support is still controversial.-Aim: To analyze the long-term outcome of PTCL patients treated with intensive first-line chemotherapy with highdose-therapy and autologous transplant consolidation. Method: Sequential chemotherapy protocol consisting of 3 cycles of CHOEP-21-like regimen (PACEBO), 1 cycle-of an ifosfamide and methotrexate-based regimen (IVAM) and a priming regimen with high-dose cytosine arabinoside-(HAM). Consolidation was provided with myeloablative conditioning ( Background: Nodal peripheral T-cell lymphomas (PTCLs) are infrequent subtypes of non-Hodgkin?s lymphomas.-The WHO classification recognizes three subgroups of nodal PTCL: peripheral T-cell lymphoma not otherwise specified-(PTCL, NOS), anaplastic large cell lymphoma (ALCL) and angioimmunoblastic lymphoma (AIL). The clinical-course is aggressive and despite multiagent chemotherapy, the median survival is about 2 years. Optimal first-line chemotherapy-is not established and the role of high-dose therapy with autologous stem cell support is still controversial.-Aim: To analyze the long-term outcome of PTCL patients treated with intensive first-line chemotherapy with highdose-therapy and autologous transplant consolidation. Method: Sequential chemotherapy protocol consisting of 3 cycles of CHOEP-21-like regimen (PACEBO), 1 cycle-of an ifosfamide and methotrexate-based regimen (IVAM) and a priming regimen with high-dose cytosine arabinoside-(HAM). Consolidation was provided with myeloablative conditioning ( (en)
Title	Prolonged survival of patients with peripheral T-Cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation Prolonged survival of patients with peripheral T-Cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation (en)
skos:prefLabel	Prolonged survival of patients with peripheral T-Cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation Prolonged survival of patients with peripheral T-Cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation (en)
skos:notation	RIV/61989592:15110/09:00009739!RIV10-MSM-15110___
http://linked.open...avai/riv/aktivita	S Z
http://linked.open...avai/riv/aktivity	S, Z(MSM6198959205)
http://linked.open...iv/cisloPeriodika	1
http://linked.open...vai/riv/dodaniDat	2010
http://linked.open...aciTvurceVysledku	Raida, Luděk Vondráková, Jana PAPAJÍK, Tomáš Faber, Edgar INDRÁK, Karel Procházka, Vít Kučerová, Ladislava Jarošová, Marie
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Palackého v Olomouci / Lékařská fakulta
http://linked.open...dnocenehoVysledku	337099
http://linked.open...ai/riv/idVysledku	RIV/61989592:15110/09:00009739
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Peripheral T-cell lymphoma; PTCL; High-dose chemotherapy; Autologous transplantation; First line (en)
http://linked.open.../riv/klicoveSlovo	PTCL Autologous transplantation First line Peripheral T-cell lymphoma High-dose chemotherapy
http://linked.open...odStatuVydavatele	CZ - Česká republika
http://linked.open...ontrolniKodProRIV	[76B355D80534]
http://linked.open...i/riv/nazevZdroje	Biomedical Papers
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	8 (xsd:int)
http://linked.open...cetTvurcuVysledku	8 (xsd:int)
http://linked.open...UplatneniVysledku	2009
http://linked.open...v/svazekPeriodika	153
http://linked.open...iv/tvurceVysledku	Faber, Edgar Indrák, Karel Jarošová, Marie Raida, Luděk Vondráková, Jana Procházka, Vít Kučerová, Ladislava Papajík, Tomáš
http://linked.open...n/vavai/riv/zamer	Studies of genes and molecular mechanisms involved in regulation of hematopoiesis, their clinical impact and targeted treatment
issn	1213-8118
number of pages	4 (xsd:int)
http://localhost/t...ganizacniJednotka	15110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 49 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software